Spots Global Cancer Trial Database for recurrent hypopharyngeal squamous cell carcinoma

Every month we try and update this database with for recurrent hypopharyngeal squamous cell carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	NCT05172258	Head and Neck S... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Pembrolizumab	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck	NCT01064479	Metastatic Squa... Metastatic Squa... Metastatic Squa... Metastatic Squa... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph...	Carboplatin Cisplatin Docetaxel Erlotinib Hydro... Laboratory Biom... Pharmacological... Placebo Quality-of-Life...	18 Years -	M.D. Anderson Cancer Center
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT01267240	Paranasal Sinus... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph...	Capecitabine Vorinostat	19 Years -	National Cancer Institute (NCI)
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT01267240	Paranasal Sinus... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph...	Capecitabine Vorinostat	19 Years -	National Cancer Institute (NCI)
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT00588770	Neck Squamous C... Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Neck ... Recurrent Oral ... Recurrent Oroph... Recurrent Saliv... Recurrent Sinon... Salivary Gland ... Stage IV Hypoph... Stage IV Major ... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Oral ... Stage IVA Oroph... Stage IVA Sinon... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Oral ... Stage IVB Oroph... Stage IVB Sinon... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Oral ... Stage IVC Oroph... Stage IVC Sinon... Tongue Carcinom...	Bevacizumab Carboplatin Cisplatin Docetaxel Fluorouracil Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck	NCT01064479	Metastatic Squa... Metastatic Squa... Metastatic Squa... Metastatic Squa... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Oral C... Stage IV Oropha... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph...	Carboplatin Cisplatin Docetaxel Erlotinib Hydro... Laboratory Biom... Pharmacological... Placebo Quality-of-Life...	18 Years -	M.D. Anderson Cancer Center
Sorafenib in Combination With Carboplatin and Paclitaxel in Treating Participants With Metastatic or Recurrent Head and Neck Squamous Cell Cancer	NCT00494182	Metastatic Head... Metastatic Squa... Metastatic Squa... Metastatic Squa... Metastatic Squa... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph...	Carboplatin Paclitaxel Sorafenib	18 Years -	M.D. Anderson Cancer Center
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	NCT00588770	Neck Squamous C... Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Neck ... Recurrent Oral ... Recurrent Oroph... Recurrent Saliv... Recurrent Sinon... Salivary Gland ... Stage IV Hypoph... Stage IV Major ... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Oral ... Stage IVA Oroph... Stage IVA Sinon... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Oral ... Stage IVB Oroph... Stage IVB Sinon... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Oral ... Stage IVC Oroph... Stage IVC Sinon... Tongue Carcinom...	Bevacizumab Carboplatin Cisplatin Docetaxel Fluorouracil Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT04862650	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a...	Carboplatin Cemiplimab Paclitaxel	18 Years -	Ohio State University Comprehensive Cancer Center
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck	NCT05172258	Head and Neck S... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Oropha...	Biopsy Biospecimen Col... Computed Tomogr... Ipatasertib Pembrolizumab	18 Years -	National Cancer Institute (NCI)
Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy	NCT01256385	Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Metas... Recurrent Nasal... Recurrent Nasop... Recurrent Oral ... Recurrent Oroph... Recurrent Saliv... Salivary Gland ... Squamous Cell C... Stage IV Hypoph... Stage IV Nasoph... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Nasal... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Nasal... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Nasal... Stage IVC Oral ... Stage IVC Oroph... Tongue Carcinom...	Cetuximab Laboratory Biom... Temsirolimus	18 Years -	National Cancer Institute (NCI)
Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	NCT04862650	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Oral... Metastatic Orop... Pathologic Stag... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Lip a... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Lip a... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Lip a...	Carboplatin Cemiplimab Paclitaxel	18 Years -	Ohio State University Comprehensive Cancer Center
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma	NCT04671667	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph...	Carboplatin Cisplatin Computed Tomogr... Intensity-Modul... Magnetic Resona... Pembrolizumab Proton Beam Rad...	18 Years - 79 Years	National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer	NCT04576091	Clinical Stage ... Clinical Stage ... Recurrent Cutan... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Recurrent Paran... Recurrent Saliv... Stage III Cutan... Stage III Hypop... Stage III Laryn... Stage III Lip a... Stage III Major... Stage III Oroph... Stage III Sinon... Stage IV Cutane... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Major ... Stage IV Oropha... Stage IV Sinona... Unresectable Cu... Unresectable He... Unresectable Hy... Unresectable La... Unresectable Or... Unresectable Or... Unresectable Pa... Unresectable Sa...	Biospecimen Col... Computed Tomogr... Elimusertib Pembrolizumab Positron Emissi... Quality-of-Life... Stereotactic Bo...	18 Years -	National Cancer Institute (NCI)
Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers	NCT05063552	Clinical Stage ... Metastatic Head... Metastatic Hypo... Metastatic Lary... Metastatic Lip ... Metastatic Nasa... Metastatic Naso... Metastatic Phar... Metastatic Sino... Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Lip a... Recurrent Nasop... Recurrent Phary... Recurrent Sinon... Stage IV Hypoph... Stage IV Laryng... Stage IV Lip an... Stage IV Nasoph... Stage IV Oropha... Stage IV Sinona...	Atezolizumab Bevacizumab Biospecimen Col... Carboplatin Cetuximab Cisplatin Computed Tomogr... Docetaxel Echocardiograph... Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery	NCT04588038	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Resectable Orop...	Efineptakin alf...	18 Years -	University of California, San Francisco
Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer	NCT01267240	Paranasal Sinus... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Stage IVA Hypop... Stage IVA Laryn... Stage IVA Oral ... Stage IVA Oroph... Stage IVB Hypop... Stage IVB Laryn... Stage IVB Oral ... Stage IVB Oroph... Stage IVC Hypop... Stage IVC Laryn... Stage IVC Oral ... Stage IVC Oroph...	Capecitabine Vorinostat	19 Years -	National Cancer Institute (NCI)
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery	NCT04588038	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Resectable Orop...	Efineptakin alf...	18 Years -	University of California, San Francisco
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma	NCT04671667	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph...	Carboplatin Cisplatin Computed Tomogr... Intensity-Modul... Magnetic Resona... Pembrolizumab Proton Beam Rad...	18 Years - 79 Years	National Cancer Institute (NCI)
Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer	NCT00458978	Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Metas... Recurrent Nasal... Recurrent Nasop... Recurrent Oral ... Recurrent Oroph... Recurrent Saliv... Salivary Gland ... Squamous Cell C... Stage IV Hypoph... Stage IV Laryng... Stage IV Laryng... Stage IV Lip an... Stage IV Major ... Stage IV Nasal ... Stage IV Nasoph... Stage IV Oral C... Stage IV Oropha... Tongue Carcinom... Untreated Metas...	Cediranib Malea... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery	NCT04588038	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph... Resectable Orop...	Efineptakin alf...	18 Years -	University of California, San Francisco
Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery	NCT02007200	Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Oral ... Recurrent Oroph... Stage I Hypopha... Stage I Larynge... Stage I Larynge... Stage I Lip and... Stage I Oral Ca... Stage I Orophar... Stage II Hypoph... Stage II Laryng... Stage II Laryng... Stage II Lip an... Stage II Oral C... Stage II Oropha... Stage III Hypop... Stage III Laryn... Stage III Laryn... Stage III Lip a... Stage III Oral ... Stage III Oroph... Stage IV Hypoph... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Oral ... Stage IVA Oroph... Tongue Carcinom...	Laboratory Biom... Soy Isoflavones Survey Administ...	19 Years - 79 Years	National Cancer Institute (NCI)
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma	NCT04671667	Recurrent Head ... Recurrent Hypop... Recurrent Laryn... Recurrent Oral ... Recurrent Oroph...	Carboplatin Cisplatin Computed Tomogr... Intensity-Modul... Magnetic Resona... Pembrolizumab Proton Beam Rad...	18 Years - 79 Years	National Cancer Institute (NCI)
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer	NCT01254617	Recurrent Colon... Recurrent Hypop... Recurrent Laryn... Recurrent Laryn... Recurrent Lip a... Recurrent Metas... Recurrent Nasal... Recurrent Nasop... Recurrent Oral ... Recurrent Oroph... Recurrent Recta... Recurrent Saliv... Salivary Gland ... Squamous Cell C... Stage IV Hypoph... Stage IV Nasoph... Stage IVA Colon... Stage IVA Laryn... Stage IVA Laryn... Stage IVA Lip a... Stage IVA Major... Stage IVA Nasal... Stage IVA Oral ... Stage IVA Oroph... Stage IVA Recta... Stage IVB Colon... Stage IVB Laryn... Stage IVB Laryn... Stage IVB Lip a... Stage IVB Major... Stage IVB Nasal... Stage IVB Oral ... Stage IVB Oroph... Stage IVB Recta... Stage IVC Laryn... Stage IVC Laryn... Stage IVC Lip a... Stage IVC Major... Stage IVC Nasal... Stage IVC Oral ... Stage IVC Oroph... Tongue Carcinom...	Cetuximab Laboratory Biom... Lenalidomide	18 Years -	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: